Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Ophthalmology and therapy·2026
Same author

The cocktail method: influence of microbubble shell homogeneity on acoustic behavior and stability.

Soft matter·2026
Same author

Development and Internal Validation of a Side-Specific Nomogram Integrating mpMRI and Biopsy Features to Guide Nerve-Sparing Decision Making in Prostate Cancer with Capsular Contact.

Cancers·2026
Same author

Long-term survival after treatment of unruptured intracranial aneurysms: A population-based perspective.

Brain & spine·2026
Same author

Risk Assessment of Intracranial Aneurysm Remnants After Microsurgical Clipping Based on 3D-Digital Subtraction Angiography.

Operative neurosurgery (Hagerstown, Md.)·2026
Same author

Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from death.

Neuron·2026

Related Experiment Video

Updated: Jun 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Resistance to anti-platelet agents.

Marco Cattaneo1

  • 1Unità di Medicina 3-Ospedale San Paolo, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano, Milano, Italy. marco.cattaneo@unimi.it

Thrombosis Research
|January 26, 2011
PubMed
Summary

Resistance to antiplatelet agents like clopidogrel is common and reduces drug effectiveness. New P2Y12 inhibitors, such as prasugrel and ticagrelor, offer a more effective solution for patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Resistance to antiplatelet agents is a growing concern in medical literature, though definitions remain unclear.
  • While aspirin resistance is infrequent, clopidogrel resistance is common, often stemming from impaired drug metabolism.
  • Clopidogrel resistance is linked to diminished clinical efficacy, posing a challenge in antiplatelet therapy.

Purpose of the Study:

  • To review the concept of antiplatelet agent resistance, particularly clopidogrel resistance.
  • To evaluate current strategies for managing clopidogrel resistance and their limitations.
  • To highlight the potential of newer P2Y12 inhibitors as a superior alternative.

Main Methods:

  • Literature review focusing on antiplatelet resistance and P2Y12 inhibitors.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

  • Analysis of the mechanisms and clinical implications of clopidogrel resistance.
  • Comparison of the efficacy of clopidogrel versus newer agents like prasugrel and ticagrelor.

    • Main Results:

    • Aspirin resistance prevalence is low.
    • Clopidogrel resistance is frequent, primarily due to inefficient metabolism to its active form.
    • Current methods for monitoring clopidogrel response are impractical and not universally effective.

    Conclusions:

    • Newer P2Y12 inhibitors, including prasugrel and ticagrelor, provide reliable inhibition of P2Y12-dependent platelet function.
    • These agents represent the most effective solution for overcoming clopidogrel resistance.
    • Widespread adoption of prasugrel and ticagrelor may improve clinical outcomes in patients requiring antiplatelet therapy.